CHALFONT ST. GILES, UK and Bangalore, INDIA – 18 May 2017 – GE Healthcare today announced that Dr. Reddy’s Laboratories Limited will install India’s first-ever FlexFactory, a single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad, India. FlexFactory will make Dr. Reddy’s biopharmaceutical manufacturing set-up more flexible and efficient, strengthening... Read more
Accelerates development timelines with faster, easier selection and scale up of clones Delivers higher titers of recombinant proteins Billerica, Massachusetts, May 16, 2017 — MilliporeSigma today announced that its CHOZN® expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic. The CHOZN® expression system is designed... Read more
Approved for Use in Europe to Identify Head and Neck Cancer Patients Most Likely to Benefit from Opdivo (nivolumab) Therapy SANTA CLARA, Calif., May 15, 2017 Agilent Technologies Inc. (NYSE: A) today announced the expanded use of Agilent’s Dako PD-L1 IHC 28-8 pharmDx test for squamous cell carcinoma of the head and neck (SCCHN), the... Read more
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher’s acquisition of Patheon. Thermo Fisher will commence a tender offer... Read more
May 12, 2017 MilliporeSigma Opens New M Lab™ Collaboration Center in Bangalore Customers can explore new technologies and solutions to address development and manufacturing challenges Simulates a GMP manufacturing environment to accelerate development of new therapies MilliporeSigma, a leading science and technology company, today announced the expansion of its M Lab™ Collaboration Center in Bangalore,... Read more
Download PDF Read more
11 May 2017 Microsaic Systems plc (“Microsaic”, “Microsaic Systems” or the “Company”) Microsaic enhances capabilities of its 4000 MiD® miniaturised mass spectrometer for bioprocessing applications Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry (MS) instruments, has developed a novel technology to enable real-time analysis of proteins in bioprocessing applications, such as in... Read more
Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more